

Universal Biosensors, Inc.  
ARBN 121 559 993

1 Corporate Avenue  
Rowville Victoria 3178  
Australia



Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)

31 January 2024

**Universal Biosensors, Inc.**

### **December 2023 Quarterly Activity Report**

Universal Biosensors, Inc. (ASX:UBI) (UBI) has today released its cash flow report (ASX Appendix 4C) and quarterly activity report for the quarter ended 31 December 2023 (Q4 2023).

UBI is developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women's health and fertility, non-human and environmental testing using our patented platform technology and hand-held point-of-use devices.

Key developments were:

- Sales for H2 2023 were up 55% on H1 2023
- Sales for an individual month exceeded \$1.0 million for the first-time during December 2023 (x Siemens)
- Regulatory approval for the sale of Xprecia Prime 4U to patients for self-testing in Europe
- The continuing development of new products
- Submission of the "full response" to FDA request for additional information for the approval of Xprecia Prime in the USA

### **FINANCIAL UPDATE**

Cash and cash equivalents as at 31 December 2023 was \$10.6 million.

Payments of \$91,000 as disclosed in item 6 of the attached Appendix 4C comprised of the non-executive directors' fees, allowances and superannuation.

For further information, please contact:

**John Sharman**

Chief Executive Officer

+61 (0) 414 440 680

***Announcement authorised by the Board of Directors of Universal Biosensors, Inc.***

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

UNIVERSAL BIOSENSORS, INC.

**ABN**

67 950 836 446

**Quarter ended ("current quarter")**

31 December 2023

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,661	5,488
1.2 Payments for		
(a) research and development	(1,182)	(3,584)
(b) product manufacturing and operating costs	(1,588)	(4,043)
(c) advertising and marketing	(219)	(688)
(d) leased assets	(265)	(919)
(e) staff costs	(3,058)	(12,118)
(f) administration and corporate costs	(1,037)	(4,118)
1.3 Dividends received (see note 3)		
1.4 Interest received	139	767
1.5 Interest and other costs of finance paid		(18)
1.6 Income taxes paid		
1.7 Government grants and tax incentives		4,478
1.8 Other (provide details if material)	34	136
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(5,515)</b>	<b>(14,619)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(400)	(1,474)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
<b>2.6 Net cash from / (used in) investing activities</b>	<b>(400)</b>	<b>(1,474)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities		(30)
3.5 Proceeds from borrowings		1,056
3.6 Repayment of borrowings	(44)	(1,100)
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)	(2)	(8)
<b>3.10 Net cash from / (used in) financing activities</b>	<b>(46)</b>	<b>(82)</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of period	16,641	26,825
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(5,515)	(14,619)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(400)	(1,474)

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(46)	(82)
4.5	Effect of movement in exchange rates on cash held	(85)	(55)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>10,595</b>	<b>10,595</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	5,740	1,786
5.2	Call deposits	4,500	14,500
5.3	Bank overdrafts	0	0
5.4	Other (provide details – refer 7.6)	355	355
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>10,595</b>	<b>16,641</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	91
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

7. <b>Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	911	911
7.2 Credit standby arrangements		
7.3 Other (please specify)	355	355
7.4 <b>Total financing facilities</b>	1,266	1,266
7.5 <b>Unused financing facilities available at quarter end</b>		0
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p><u>7.1 Loan facilities:</u> The secured loan is a short-term loan facility the Company entered into to finance its 2024 insurance premium. The total amount financed was A\$911,082, and has the following terms</p> <ul style="list-style-type: none"> <li>• the facility is repayable in 9 monthly instalments which commenced in January 2024;</li> <li>• interest is being charged at an effective annual interest rate of 1.99%; and</li> <li>• the short-term borrowing is secured by proceeds of or payable under any insurance including proceeds or refunds from the cancellation or termination of any insurance.</li> </ul> <p><u>7.3 Collateral for facilities</u> represents bank guarantee of A\$250,000 for commercial lease of UBS' premises and security deposit on Company's credit cards of A\$105,000.</p>		

8. <b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(5,515)
8.2 Cash and cash equivalents at quarter end (item 4.6)	10,595
8.3 Unused finance facilities available at quarter end (item 7.5)	0
8.4 Total available funding (item 8.2 + item 8.3)	10,595
8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	1.9
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
<p>Answer: No – The Company spent \$1.8m during the period on non-recurring capital items and product development, including costs relating to the FDA application for Xprecia Prime. The Company also spent \$1.2m on inventory relating to new products launched in markets around the world.</p>	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

The company believes it has sufficient cash reserves and is closely monitoring the success of its commercialization efforts in relation to the newly launched product portfolio and their impact on the cash position.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Yes – refer comments in 8.6.1 and 8.6.2

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 January 2024

Authorised by: By the board  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.